Parkin Levels Decrease in Fibroblasts With Progranulin (PGRN) Pathogenic Variants and in a Cellular Model of PGRN Deficiency.

Katarzyna Gaweda-Walerych, Dawid Walerych, Mariusz Berdyński, Emanuele Buratti, Cezary Zekanowski
Author Information
  1. Katarzyna Gaweda-Walerych: Laboratory of Neurogenetics, Mossakowski Medical Research Institute, Department of Neurodegenerative Disorders, Polish Academy of Sciences, Warsaw, Poland.
  2. Dawid Walerych: Laboratory of Human Disease Multiomics, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.
  3. Mariusz Berdyński: Laboratory of Neurogenetics, Mossakowski Medical Research Institute, Department of Neurodegenerative Disorders, Polish Academy of Sciences, Warsaw, Poland.
  4. Emanuele Buratti: Molecular Pathology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
  5. Cezary Zekanowski: Laboratory of Neurogenetics, Mossakowski Medical Research Institute, Department of Neurodegenerative Disorders, Polish Academy of Sciences, Warsaw, Poland.

Abstract

Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are neurodegenerative diseases with TDP-43 mislocalization and aggregation. Genetic forms of FTLD and ALS are caused by pathogenic variants in various genes, such as (progranulin). To date, depletion of parkin E3 ubiquitin protein ligase, a key mitophagy regulator, has been reported in sporadic ALS patients and ALS mice models with TDP-43 proteinopathy. In this work, we show parkin downregulation also in fibroblasts derived from FTLD patients with four different PGRN pathogenic variants. We corroborate this finding in control fibroblasts upon PGRN silencing, demonstrating additionally the decrease of parkin downstream targets, mitofusin 2 (MFN2) and voltage dependent anion channel 1 (VDAC1). Importantly, we show that TDP-43 overexpression rescues PRKN levels upon transient PGRN silencing, but not in FTLD fibroblasts with PGRN pathogenic variants, despite upregulating PGRN levels in both cases. Further observation of PRKN downregulation upon TDP-43 silencing, suggests that TDP-43 loss-of-function contributes to PRKN decrease. Our results provide further evidence that parkin downregulation might be a common and systemic phenomenon in neurodegenerative diseases with TDP- 43 loss-of-function.

Keywords

References

  1. Int Rev Neurobiol. 2019;149:249-275 [PMID: 31779815]
  2. Hum Mol Genet. 2017 Mar 1;26(5):969-988 [PMID: 28073925]
  3. J Cell Biol. 2010 Apr 19;189(2):211-21 [PMID: 20404107]
  4. Cell Death Dis. 2018 Sep 20;9(10):953 [PMID: 30237395]
  5. Protein Cell. 2016 Feb;7(2):114-29 [PMID: 26746706]
  6. J Biol Chem. 2012 May 4;287(19):15635-47 [PMID: 22427648]
  7. Acta Neurobiol Exp (Wars). 2013;73(2):199-224 [PMID: 23823983]
  8. Neuron. 2015 Jan 21;85(2):257-73 [PMID: 25611507]
  9. Mol Cell Neurosci. 2019 Oct;100:103396 [PMID: 31445085]
  10. EMBO J. 2011 Jan 19;30(2):277-88 [PMID: 21131904]
  11. Parkinsonism Relat Disord. 2018 Oct;55:145-147 [PMID: 29910155]
  12. Hum Mol Genet. 2013 Dec 1;22(23):4706-19 [PMID: 23827948]
  13. J Neuropathol Exp Neurol. 2019 Dec 1;78(12):1124-1129 [PMID: 31626287]
  14. Neurobiol Aging. 2015 May;36(5):2005.e5-2005.e13 [PMID: 25792239]
  15. Nat Neurosci. 2011 Apr;14(4):459-68 [PMID: 21358643]
  16. J Cell Biol. 2008 Dec 1;183(5):795-803 [PMID: 19029340]
  17. Mol Neurodegener. 2018 Sep 4;13(1):48 [PMID: 30180904]
  18. Mol Cell. 2014 May 8;54(3):378-91 [PMID: 24703948]
  19. Cell Death Dis. 2019 Jul 8;10(7):524 [PMID: 31285425]
  20. J Neurochem. 2011 Aug;118(4):636-45 [PMID: 21615408]
  21. Neurosci Lett. 2018 Jun 21;678:8-15 [PMID: 29715546]
  22. PLoS Biol. 2010 Jan 26;8(1):e1000298 [PMID: 20126261]
  23. Acta Neuropathol Commun. 2016 May 05;4(1):47 [PMID: 27151080]
  24. Nat Neurosci. 2012 Nov;15(11):1488-97 [PMID: 23023293]
  25. J Neurochem. 2016 Aug;138 Suppl 1:95-111 [PMID: 27015757]
  26. EMBO Mol Med. 2018 Oct;10(10): [PMID: 30126943]
  27. Nature. 2006 Aug 24;442(7105):916-9 [PMID: 16862116]
  28. Cell Rep. 2017 Sep 12;20(11):2565-2574 [PMID: 28903038]
  29. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21510-5 [PMID: 23236149]
  30. Nature. 2006 Aug 24;442(7105):920-4 [PMID: 16862115]
  31. EMBO J. 2012 Mar 21;31(6):1336-49 [PMID: 22354038]
  32. Hum Mol Genet. 2016 Feb 1;25(3):534-45 [PMID: 26614389]
  33. Acta Neuropathol. 2018 Jul;136(1):1-17 [PMID: 29744576]
  34. FEBS J. 2010 May;277(10):2268-81 [PMID: 20423455]
  35. Nat Med. 2016 Aug;22(8):869-78 [PMID: 27348499]
  36. J Biol Chem. 2013 Feb 8;288(6):4103-15 [PMID: 23258539]
  37. Ann Neurol. 2008 Nov;64(5):555-65 [PMID: 19067348]
  38. Trends Cell Biol. 2015 Mar;25(3):158-70 [PMID: 25499735]
  39. Nat Methods. 2012 Jul;9(7):671-5 [PMID: 22930834]
  40. Neurobiol Aging. 2018 Dec;72:186.e9-186.e12 [PMID: 30057241]
  41. Science. 2006 Oct 6;314(5796):130-3 [PMID: 17023659]

Word Cloud

Created with Highcharts 10.0.0PGRNTDP-43parkinFTLDALSfibroblastspathogenicvariantsdownregulationuponsilencingPRKNlobardegenerationneurodegenerativediseasesprogranulinpatientsshowdecreaselevelsloss-of-functionFrontotemporalamyotrophiclateralsclerosismislocalizationaggregationGeneticformscausedvariousgenesdatedepletionE3ubiquitinproteinligasekeymitophagyregulatorreportedsporadicmicemodelsproteinopathyworkalsoderivedfourdifferentcorroboratefindingcontroldemonstratingadditionallydownstreamtargetsmitofusin2MFN2voltagedependentanionchannel1VDAC1ImportantlyoverexpressionrescuestransientdespiteupregulatingcasesobservationsuggestscontributesresultsprovideevidencemightcommonsystemicphenomenonTDP-43ParkinLevelsDecreaseFibroblastsProgranulinPathogenicVariantsCellularModelDeficiencyfrontotemporalprimarydeficiency

Similar Articles

Cited By